234 related articles for article (PubMed ID: 27898496)
1. Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone.
Hser YI; Huang D; Saxon AJ; Woody G; Moskowitz AL; Matthews AG; Ling W
J Addict Med; 2017; 11(1):63-69. PubMed ID: 27898496
[TBL] [Abstract][Full Text] [Related]
2. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
6. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI
J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695
[TBL] [Abstract][Full Text] [Related]
7. Short term health-related quality of life improvement during opioid agonist treatment.
Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
9. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
Dalton K; Butt N
J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
[TBL] [Abstract][Full Text] [Related]
10. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
11. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
12. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Zhu Y; Mooney LJ; Yoo C; Evans EA; Kelleghan A; Saxon AJ; Curtis ME; Hser YI
Drug Alcohol Depend; 2021 Nov; 228():108996. PubMed ID: 34555691
[TBL] [Abstract][Full Text] [Related]
14. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Lugoboni F; Zamboni L; Cibin M; Tamburin S;
Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
[TBL] [Abstract][Full Text] [Related]
15. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
18. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
[TBL] [Abstract][Full Text] [Related]
19. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
[TBL] [Abstract][Full Text] [Related]
20. Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial.
Socias ME; Cui Z; Le Foll B; Lei J; Stewart S; Anand R; Jutras-Aswad D
HIV Med; 2024 Jul; 25(7):817-825. PubMed ID: 38506171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
